SCHEMBL7984900

SCHEMBL7984900

COc1ccc(CN2Cc3ccc(C(=O)O)cc3C2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HDAC6 Q9UBN7 5/20 0.47
HDAC1 Q13547 5/20 0.45
HDAC4 P56524 3/20 0.45
TAS2R14 Q9NYV8 1/20 0.45
NPC1 O15118 2/20 0.45
POLB P06746 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
ADAM17 P78536 5/20 0.44
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7979501 0.91 L3MBTL1 (0.53) L3MBTL1MEN1KMT2AHDAC6HDAC1
SCHEMBL1418461 0.89 KMT2A (0.53) MEN1KMT2AHDAC6HDAC1HDAC4
SCHEMBL6442206 0.86 ADAM17 (0.56) MEN1KMT2APOLBADAM17
SCHEMBL27086033 0.86 PTGS1 (0.49) MEN1KMT2AHDAC6HDAC1HDAC4
SCHEMBL1418406 0.85 CACNA1G (0.50) MEN1KMT2AHDAC6HDAC1MAPT
SCHEMBL6767486 0.85 MEN1 (0.49) MEN1KMT2AHDAC6HDAC1HDAC4
SCHEMBL2065219 0.85 HDAC1 (0.59) L3MBTL1MEN1KMT2AHDAC6HDAC1
SCHEMBL12446495 0.85 HDAC1 (0.49) MEN1KMT2AHDAC6HDAC1HDAC4
SCHEMBL6762069 0.82 CA1 (0.49) MEN1KMT2AHDAC6HDAC1HDAC4
SCHEMBL27085935 0.82 HDAC6 (0.50) MEN1KMT2AHDAC6HDAC1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117229281-A Di-parallel ring derivative regulator, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-12-15 CN disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 L3MBTL1 3118/4885MEN1 2484/4885KMT2A 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.